The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
The new Zigly center features and offers comprehensive veterinary services
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Subscribe To Our Newsletter & Stay Updated
